3Fedak PW,Altamentova SM,Weisel RD,et al.Matrix remodeling in experimental and human heart failure:A possible regulatory role for TIMP-3[J].Am J Physiol Heart Circ Physiol,2003,284:626-634.
4Khan A,Moe GW,Nili N,et al.The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure[J].J Am Coll Cardiol,2004,43:68-76.
5Kaden JJ,Dempfle CE,Sueselbeck T,et al.Time-dependent in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction[J].Cardiology,2003,99:140-144.
7Hayashidani S,Tsutsui H,Ikeuchi M,et al.Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction[J].Am J Physiol Heart Circ Physiol,2003,285:1229-1235.
8Li J,Schwimmbeck PL,Tschope C,et al.Collagen degradation in a murine myocarditis model:relevance of matrix metalloproteinase in association with inflammatory induction[J].Cardiovac Res,2002,56:235-247.
10Nakano Y,Niida S,Dote K,et al.Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation[J].J Am Coll Cardiol,2004,43:818-825.
二级参考文献30
1Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
3Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
4Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
5Ducharme A , Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
6Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
7Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure,1993,8 : 230-238.
8Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation, 1998, 98 : 1728-1734.
9Roten L, Nemoto S, Simsic J, et al. Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 ( TIMP-1 ) on left ventricular geometry and function in mice. J Mol Cell Cardiol,2000, 32:109-120.
10Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation . Circulation, 1997, 96: 1180-1184.
